Boston Scientific Corporation $BSX Shares Purchased by Valeo Financial Advisors LLC

Valeo Financial Advisors LLC grew its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 1.9% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 22,038 shares of the medical equipment provider’s stock after purchasing an additional 417 shares during the quarter. Valeo Financial Advisors LLC’s holdings in Boston Scientific were worth $2,367,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of BSX. 1248 Management LLC acquired a new position in shares of Boston Scientific during the first quarter valued at about $26,000. Y.D. More Investments Ltd acquired a new position in shares of Boston Scientific during the first quarter valued at about $27,000. Sound Income Strategies LLC increased its holdings in shares of Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 120 shares in the last quarter. Oliver Lagore Vanvalin Investment Group acquired a new position in shares of Boston Scientific during the second quarter valued at about $37,000. Finally, Activest Wealth Management increased its holdings in Boston Scientific by 6,216.7% in the 1st quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock worth $38,000 after buying an additional 373 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Trading Down 0.6%

Boston Scientific stock opened at $96.73 on Tuesday. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50. The stock’s 50 day simple moving average is $102.75 and its two-hundred day simple moving average is $102.04. The firm has a market cap of $143.33 billion, a PE ratio of 57.58, a P/E/G ratio of 2.34 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter last year, the firm posted $0.62 EPS. The business’s revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on BSX shares. Royal Bank Of Canada reiterated an “outperform” rating and issued a $125.00 price target on shares of Boston Scientific in a report on Monday, September 29th. Leerink Partners increased their price target on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Erste Group Bank downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday. Raymond James Financial increased their price target on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a report on Thursday, July 24th. Finally, Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $118.00 to $125.00 in a report on Monday, September 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, Boston Scientific presently has a consensus rating of “Buy” and a consensus target price of $120.79.

Insiders Place Their Bets

In other news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. This trade represents a 42.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $5,231,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at $18,659,923.46. This trade represents a 21.90% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 174,214 shares of company stock worth $17,972,457. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.